Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | Director | March 31, 2006 | April 04, 2006 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2025 | May 03, 2025 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | July 22, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2006 · Filed April 04, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 22,932.28 |
Reported balance
After 2006-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-03-31 · Grant · Acquired 203.63 · Balance 22,932.28 F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director.
Emergent BioSolutions Inc.
Report date April 30, 2025 · Filed May 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,098 |
Reported balance
After 2025-04-30 transaction · row 1
1 source rowRow 1 · 2025-04-30 · Grant · Acquired 34,403 · Balance 139,098 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 · Expires 2032-04-29 | Direct | 41,572 |
Reported balance
After 2025-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-30 · Grant · Acquired 15,824 · Balance 41,572 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
UNITED THERAPEUTICS Corp
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22 | Direct | 2,380 |
Reported balance
After 2026-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-22 · Grant · Acquired 2,380 · Balance 2,380 F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. |
| Common StockSEC Table I · non-derivative | Direct | 2,983 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,983 F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 1,457 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,457 F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026.
F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.
F3: Annual non-employee director award.
F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2018 Filed Oct 2, 2018 20:11 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-028999 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:11 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $125.96 | $125,960.00 |
DisclosureSEC source: 0001127602-18-028999 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:11 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-18-028999 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-026783 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $119.45 | $119,450.00 |
DisclosureSEC source: 0001127602-18-026783 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-18-026783 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-024427 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $116.66 | $116,660.00 |
DisclosureSEC source: 0001127602-18-024427 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-18-024427 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-022828 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $113.81 | $113,810.00 |
DisclosureSEC source: 0001127602-18-022828 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-18-022828 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 1,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021985 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F6 · derivative.exercise_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. F6 · derivative.expiration_date: Restricted stock units were granted on June 28, 2017, and vested on June 28, 2018. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 23:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021985 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 28, 2018. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-021985 · form4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 15,000 | $0.00 Strike: $51.77 | $0.00 |
DisclosureSEC source: 0001127602-18-020138 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of a cash-settled share tracking award Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 15,000 | $108.50 | $1,627,500.00 |
DisclosureSEC source: 0001127602-18-020138 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 F1 · kind: Exercise of a cash-settled share tracking award Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $51.77 | $776,550.00 |
DisclosureSEC source: 0001127602-18-020138 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of a cash-settled share tracking award Read SEC document |
| May 24, 2018 Filed May 24, 2018 20:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025518 · doc1.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. F3 · balance_after: The amount of securities beneficially owned includes the correction of a mathematical error reported in a Form 4 filed on May 26, 2017. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 20:22 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 4,210 | $0.00 Strike: $132.30 | $0.00 |
DisclosureSEC source: 0001127602-17-022461 · form4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,210 Underlying: Common Stock · 4,210 shares Expires 2027-06-28 F2 · shares: Annual non-employee director grant of restricted stock units and/or stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 20:22 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 1,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-022461 · form4.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,620 Underlying: Common Stock · 1,620 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director grant of restricted stock units and/or stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F3 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F3 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 1,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-022045 · form4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert on a one-for-one basis into shares of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 21, 2016, and vested on June 21, 2017. The entire number of restricted stock units converted into shares of common stock upon vesting. F3 · derivative.expiration_date: The restricted stock units were granted on June 21, 2016, and vested on June 21, 2017. The entire number of restricted stock units converted into shares of common stock upon vesting. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-022045 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 21, 2017. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| May 25, 2017 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · nonDerivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,077 F4 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F5 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) (Common Stock) · Derivative | 905 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 9 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,305 Underlying: Common Stock · 10,305 shares Expires 2021-05-22 F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) (Common Stock) · Derivative | 693 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 8 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 7,893 shares Expires 2020-05-23 F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F7 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) (Common Stock) · Derivative | 693 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 7 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 7,893 shares Expires 2019-05-17 F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F7 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 693 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 6 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 7,893 shares Expires 2021-05-19 F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F7 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 693 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 5 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 7,893 shares Expires 2020-05-20 F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F7 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,241 F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018. Read SEC document |
| August 01, 2016 Filed May 26, 2017 17:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 152 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022461 · doc1.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,637 F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017. Read SEC document |
| June 21, 2016 Filed Mar 7, 2017 21:59 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 4,910 | $0.00 Strike: $101.80 | $0.00 |
DisclosureSEC source: 0001127602-17-010634 · form4a.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2026-06-21 F1 · shares: The purpose of this amendment is to correct an overstatement of the number of shares subject to the stock option awarded to the reporting person on June 21, 2016, by 90 shares. The original Form 4 filing on June 23, 2016 reported 5,000 shares subject to this stock option. Read SEC document |
| March 31, 2006 Filed Apr 4, 2006 21:05 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 203.63 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-06-000125 · sul552.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,932.28 Underlying: Common Stock, $0.10 par value · 203.63 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| February 01, 2006 Filed Feb 3, 2006 21:38 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-06-000043 · sul503.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,722.39 Underlying: Common Stock, $0.10 par value · 2,000 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| December 30, 2005 Filed Jan 4, 2006 20:38 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 184.62 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-06-000017 · sul486.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,478.8 Underlying: Common Stock, $0.10 par value · 184.62 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| September 30, 2005 Filed Oct 4, 2005 19:33 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 210.11 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000179 · sul450.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,028.65 Underlying: Common Stock, $0.10 par value · 210.11 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| June 30, 2005 Filed Jul 5, 2005 21:49 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 265.36 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000145 · sul422.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,599.25 Underlying: Common Stock, $0.10 par value · 265.36 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| May 03, 2005 Filed May 5, 2005 19:10 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0000014272-05-000119 · sul397.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock, $0.10 par value · 2,500 shares Expires 2015-05-02 F1 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| April 29, 2005 Filed May 3, 2005 20:50 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 4,207 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0000014272-05-000097 · sul383.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 4,207 shares Expires 2005-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Currently Exercisable. Read SEC document |
| April 29, 2005 Filed May 3, 2005 20:50 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,518 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000097 · sul383.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,399.89 F1 · shares: Shares withheld for payment of taxes upon exercise of stock option. Read SEC document |
| April 29, 2005 Filed May 3, 2005 20:50 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,207 | $15.44 | $64,956.08 |
DisclosureSEC source: 0000014272-05-000097 · sul383.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,917.89 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2005 Filed Apr 4, 2005 19:45 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 214.74 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000091 · sul378.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,128.64 Underlying: Common Stock, $0.10 par value · 214.74 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| February 01, 2005 Filed Feb 3, 2005 20:21 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000043 · sul350.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,913.9 Underlying: Common Stock, $0.10 par value · 2,000 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| December 31, 2004 Filed Jan 4, 2005 22:42 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 212.8 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000018 · sul336.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,715.08 Underlying: Common Stock, $0.10 par value · 212.8 shares Expires not disclosed F1 · derivative.exercise_price: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. Read SEC document |
| September 30, 2004 Filed Oct 4, 2004 19:10 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 213.49 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000183 · sul307.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,307.15 Underlying: Common Stock, $0.10 par value · 213.49 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2004 Filed Jul 6, 2004 19:18 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 238.97 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000147 · sul283.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,900.42 Underlying: Common Stock, $0.10 par value · 238.97 shares Expires not disclosed F1 · derivative.exercise_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F1 · derivative.expiration_date: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 04, 2004 Filed May 5, 2004 20:36 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $25.70 | $0.00 |
DisclosureSEC source: 0000014272-04-000132 · sul267.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock, $0.10 par value · 2,500 shares Expires 2014-05-03 F1 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 16:26 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 4,207 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0000014272-04-000106 · sul254.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 4,207 shares Expires 2004-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Currently Exercisable. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 16:26 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,231 | $24.80 | $55,328.80 |
DisclosureSEC source: 0000014272-04-000106 · sul254.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,687.67 F1 · shares: Shares withheld for payment of exercise price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.